Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Conshohocken, Pennsylvania. The company focuses on the development and commercialization of targeted therapeutics for metabolic diseases and liver conditions. Its lead product candidate is resmetirom, a selective thyroid hormone receptor-beta agonist designed to treat non-alcoholic steatohepatitis and liver fibrosis. Revenue is primarily generated from product sales and pharmaceutical licensing or collaborative research agreements. The company serves healthcare providers, hepatology specialists, and patients within metabolic and liver disease markets. Madrigal Pharmaceuticals Inc is publicly traded on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Madrigal Pharmaceuticals.
- Legal name
- Madrigal Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
- Exposure themes
- MASH, Metabolic Disease, Obesity & Metabolic Health
Funds holding Madrigal Pharmaceuticals
- Polar Capital Biotechnology Fund — Polar Capital · 3.9 % (largest positions only, October 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.2 % (largest positions only, September 2026)
- Polar Capital Healthcare Discovery Fund — Polar Capital · 2.7 % (largest positions only, October 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.76 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.59 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.07 % (full portfolio disclosed, September 2026)